Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2019 - Prof. Subodh Verma, MD, PhD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD
Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.

DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit
Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.

Diabetes summit Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.

Effects of SGLT2 inhibitor on clinical outcomes in acute decompensated HF patients

Literature - Jan. 14, 2020 - Damman K et al., - Eur J Heart Fail. 2020

This pilot RCT in acute decompensated HF patients showed that empagliflozin did not result in reduction of primary endpoints, but did reduce a combined endpoint of worsening HF, rehospitalization for HF or death compared to placebo.

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit
Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.

Diabetes summit Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2019 - Prof. Subodh Verma, MD, PhD
Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment (liraglutide and semaglutide) in T2DM patients with peripheral artery disease.

Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment in T2DM patients with peripheral artery disease.

Expanding opportunities for SGLT2i in clinical cardiology

EBAC-accredited E-Learning

Online-CME - This course consists of 3 lectures.
This course consists of 3 lectures.

This e-learning module addresses the effects of SGLT2 inhibition in cardiorenal syndrome. Member registration (free) is needed to enroll in this course.

Impacting progression and outcomes of DKD: Translating novel insights with GLP-1RA to practice

EBAC-accredited E-Learning

Online-CME - This course consists of 3 lectures.
This course consists of 3 lectures.

This e-learning course focusses on the effect of GLP-1RAs on kidney outcomes in diabetes patients. Member registration (free) is needed to enroll in this course.

Real-world data show kidney benefit of initiating SGLT2i vs. other glucose-lowering drugs in T2DM

Literature - Jan. 6, 2020 - Lambers Heerspink HJ et al., - Lancet Diabetes Endocrinol. 2020

The CVD-REAL 3 study assessed the rate of eGFR decline and other kidney outcomes in T2DM patients who started SGLT2i treatment compared with other glucose-lowering agents

No improvement in exercise ability with SGLT2i in two HF trials, one in HFrEF and one in HFpEF patients

News - Jan. 6, 2020

Results of the EMPERIAL-Reduced and EMPERIAL-Preserved trials were announced, which both showed no benefit in exercise ability with use of empagliflozin in HFrEF and HFpEF patients, respectively.

SGLT2 inhibition in CKD: Discussing the key questions and evidence

EBAC-accredited E-Learning

Online-CME - This course consists of 3 lectures.
This course consists of 3 lectures.

This video series addresses the effect of SGLT2i on kidney outcomes in diabetes patients with chronic kidney disease (CKD). Member registration (free) is needed to enroll in this course.

FDA approves new indication for icosapent ethyl in high CV risk patients

News - Dec. 17, 2019

Icosapent ethyl has now been approved by the FDA to reduce CV risk in adult patients with elevated triglyceride levels (≥150 mg/dL) and established CVD or T2DM and ≥two additional CV risk factors.

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD
Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.

Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.